Comparison of Hemodynamic Parameters in Healthy Volunteers: Intravenous Versus Oral Fluid Therapy

The primary objective of this study is to investigate **hemodynamic parameters** by comparing intravenous fluid therapy to oral fluid therapy in healthy volunteers. This comparison is clinically relevant as it may provide insights into the efficacy and safety of different fluid administration routes, potentially influencing clinical decisions regarding fluid management in various medical settings.

The clinical trial involves a study population comprising both **male** and **female** participants, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The focus of the study is on evaluating **hemodynamic parameters** by comparing intravenous fluid therapy to oral fluid therapy. The sponsor has not provided information regarding the total number of participants involved in the trial. The selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed to evaluate **hemodynamic parameters** by comparing intravenous fluid therapy to oral fluid therapy in healthy volunteers. This study is a Phase 3 trial, which is typically conducted to confirm the effectiveness of a treatment, monitor side effects, and collect information that will allow the treatment to be used safely. The trial is expected to commence recruitment on February 3, 2025, and conclude by April 30, 2025. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit is crucial to ensure that only suitable candidates are enrolled in the study. Following the inclusion visit, participants will attend scheduled follow-up visits, where they will receive either oral or intravenous fluids as per the randomization protocol. These visits are designed to monitor the participants' health status and collect data on the primary and secondary endpoints of the study. The sequence and frequency of these visits are structured to ensure comprehensive data collection while maintaining participant safety.

The end-of-study visit marks the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the outcomes of the intervention. The expected length of participant involvement is approximately three months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information on the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on February 3, 2025, with an estimated completion date of April 30, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data, adhering to the standards expected in a Phase 3 clinical trial. The study will focus on evaluating the treatment's impact on the specified medical condition, utilizing appropriate tools and instruments as per the trial's design. The results will contribute to understanding the treatment's potential benefits and inform future clinical decisions.